Received Jan 2, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TDAP | TDAP (BOOSTRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | UNK | — |
| TDAP | TDAP (BOOSTRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | UNK | — |
accidental administration of Tdap vaccine twice in 3 week period during pregnancy; accidental administration of Tdap vaccine twice in 3 week period during pregnancy; accidental administration of Tdap vaccine twice in 3 week period during pregnancy; This non-serious prospective pregnancy case was reported by a other health professional via call center representative and described the occurrence of extra dose administered in a female patient who received DTPa (Reduced antigen) (Boostrix) for prophylaxis. Co-suspect products included DTPa (Reduced antigen) (Boostrix) for prophylaxis. On an unknown date, the patient received the 2nd dose of Boostrix and the 1st dose of Boostrix. On an unknown date, an unknown time after receiving Boostrix and not applicable after receiving Boostrix, the patient experienced extra dose administered (Verbatim: accidental administration of Tdap vaccine twice in 3 week period during pregnancy), vaccine exposure during pregnancy (Verbatim: accidental administration of Tdap vaccine twice in 3 week period during pregnancy) and vaccine exposure during pregnancy (Verbatim: accidental administration of Tdap vaccine twice in 3 week period during pregnancy). The outcome of the extra dose administered, vaccine exposure during pregnancy and vaccine exposure during pregnancy were not applicable. Pregnancy exposure: Pregnancy Exposure (Boostrix): Trimester unknown Pregnancy Exposure (Boostrix): Trimester unknown Pregnancy Outcome: Pregnancy was ongoing Additional Information: GSK Receipt Date:15-DEC-2025 Reporter requested recommendations regarding the accidental administration of the Tdap vaccine twice within a three-week period during pregnancy. The batch number was not provided and a request for this information has been made.